Want to see POM full AI Analyst Report?
PomDoctor Ltd. Unsponsored ADR (POM) AI Stock Analysis
PomDoctor Ltd. Unsponsored ADR
(NASDAQ:POM)
PomDoctor receives the lowest possible score due to critical fundamental weaknesses and overwhelming bearish technical momentum. Accelerating cash burn, a highly leveraged balance sheet, and deepening losses present massive insolvency risks, which are fully mirrored by the stock's severe downtrend and lack of valuation support.
PomDoctor Ltd. Unsponsored ADR (POM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.22M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.96M
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 2.52
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 165
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
PomDoctor Ltd. Unsponsored ADR Business Overview & Revenue Model
Company Description
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for m...
PomDoctor Ltd. Unsponsored ADR Financial Statement Overview
Summary
Despite consistent top-line growth, the company faces severe financial distress. Deepening net losses, a massive equity deficit, and accelerating operational cash burn point to critical liquidity and solvency risks.
Income Statement
30NegativeBalance Sheet
15Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 345.02M | 399.91M | 342.56M | 304.85M | 245.22M | 215.38M |
| Gross Profit | 40.30M | 52.28M | 47.69M | 38.72M | 54.86M | 52.51M |
| EBITDA | -255.47M | -117.90M | -24.27M | -22.99M | -3.81M | -58.58M |
| Net Income | -288.80M | -212.58M | -143.36M | -145.39M | -125.51M | -188.40M |
Balance Sheet | ||||||
| Total Assets | 11.22M | 107.56M | 46.23M | 66.31M | 48.62M | 19.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.86M | 9.58M | 7.65M | 6.72M | 2.49M | 2.17M |
| Total Debt | 66.36M | 454.94M | 441.10M | 413.29M | 361.24M | 341.26M |
| Total Liabilities | 85.85M | 588.85M | 2.14B | 2.03B | 1.95B | 1.80B |
| Stockholders Equity | -69.36M | -453.97M | -2.26B | -2.12B | -1.97B | -1.85B |
Cash Flow | ||||||
| Free Cash Flow | -128.77M | -149.49M | -16.17M | -45.91M | -22.02M | -15.68M |
| Operating Cash Flow | -126.98M | -148.48M | -16.13M | -45.80M | -22.02M | -15.68M |
| Investing Cash Flow | -1.14M | -1.61M | -33.37K | -111.89K | 0 | -500.00K |
| Financing Cash Flow | 137.33M | 153.93M | 17.02M | 50.07M | 22.49M | 5.44M |
PomDoctor Ltd. Unsponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POM, the sentiment is Negative. The current price of 1.76 is below the 20-day moving average (MA) of 2.13, below the 50-day MA of 2.58, and below the 200-day MA of 9.50, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 47.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POM.
PomDoctor Ltd. Unsponsored ADR Risk Analysis
PomDoctor Ltd. Unsponsored ADR disclosed 91 risk factors in its most recent earnings report. PomDoctor Ltd. Unsponsored ADR reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPomDoctor Ltd. Unsponsored ADR Peers Comparison
Overall Rating
PETS48Neutral
LFMD44Neutral
YI40Underperform- POM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PETS | 48Neutral | $25.80M | -0.87 | -91.67% | ― | -19.67% | 34.91% |
| LFMD | 44Neutral | $110.38M | -4.55 | -179.12% | ― | -16.73% | -143.95% |
| YI | 40Underperform | $25.04M | -1.63 | 23.64% | ― | -23.90% | -45.45% |
| POM | 37Underperform | $4.91M | -0.20 | 79.79% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| POM | PomDoctor Ltd. Unsponsored ADR | 1.85 | -345.55 | -99.47% | |
| PETS | Petmed Express | 1.20 | -1.27 | -51.42% | |
| YI | 111, Inc. | 2.92 | -1.52 | -34.23% | |
| LFMD | Lifemd, Inc. | 2.31 | -3.11 | -57.38% |
PomDoctor Ltd. Unsponsored ADR Corporate Events
PomDoctor to Terminate ADRs and Launch Direct Nasdaq Listing on October 21
PomDoctor Limited has moved to overhaul its U.S. listing structure following board approval on September 3, 2026 and a non-binding shareholder vote on September 30, 2026. On October 19, 2026, the company announced it will terminate its American Depos...
Pomdoctor Faces Nasdaq Delisting After Prolonged Bid-Price Noncompliance
Pomdoctor Limited disclosed that on October 6, 2026 it received a Nasdaq staff determination letter stating its American depositary shares had closed below $1.00 for 30 consecutive trading days from August 24 to October 5, 2026, breaching Nasdaq̵...
PomDoctor Shareholders Back ADR Exit and 10-for-1 Share Consolidation
On September 30, 2026, PomDoctor Limited held an extraordinary general meeting in Guangzhou to consider changes to its U.S. market listing structure and share capital. Shareholders representing 53,070,520 votes were present or represented by proxy, e...
Pomdoctor Advances AI Chronic Disease Platform and Real-World Data Commercialization
On September 30, 2026, Pomdoctor Limited announced further progress in its AI-enabled chronic disease management ecosystem, highlighting multiple rounds of optimization of its proprietary system using multidimensional real-world healthcare data. The...
PomDoctor Files Mid‑Year 2026 Unaudited Results with U.S. SEC
PomDoctor Limited has filed a Form 6‑K with the U.S. Securities and Exchange Commission dated September 29, 2026, furnishing unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025 and 2026. The subm...
Pomdoctor Showcases Integrated ‘Hardware + AI + Payment’ Model to Redefine Digital Healthcare Infrastructure
On September 24, 2026, Pomdoctor Limited highlighted its differentiated “hardware + AI + payment” digital healthcare infrastructure model, which integrates continuous health monitoring, AI-driven analysis, physician services and embedded...
Pomdoctor to Showcase AI-Driven Healthcare Strategy at H.C. Wainwright Global Investment Conference
Pomdoctor Ltd., a Guangzhou-based digital healthcare company traded on Nasdaq, specializes in AI-enabled healthcare and predictive analytics, combining physician resources, wearables, artificial intelligence, payment networks and real-world data to p...
PomDoctor Sets September Vote on ADR Termination and 10-for-1 Share Consolidation
PomDoctor Limited, a Cayman Islands-incorporated company based in Guangzhou and traded on Nasdaq as POM, operates with American depositary shares representing its Class A ordinary shares for U.S. investors. The company maintains a dual-class structur...
Pomdoctor Launches U.S. Expansion Preparations With AI-Driven Healthcare Strategy
Pomdoctor Limited, a digital healthcare firm focused on AI-driven predictive healthcare, operates an established platform in China that combines physician resources, wearables, payment networks and real-world data to support continuous, personalized...
Pomdoctor Unveils AI-Powered Healthcare Intelligence Flywheel to Drive Predictive Growth
Pomdoctor Limited, a digital healthcare company based in Guangzhou and listed on NASDAQ, develops AI-enabled healthcare and predictive health services that integrate physician resources, wearable devices, healthcare payment networks and real-world he...
Pomdoctor Unveils Four-Tier Revenue Model to Drive AI-Enabled Healthcare Growth
On August 3, 2026, Pomdoctor Limited outlined a four-tier diversified revenue structure designed to anchor its established B2C internet hospital and pharmaceutical supply chain operations while scaling technology-driven services. The company reported...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026